David Kijlstra, MD-PhD
Chief Executive Officer
David Kijlstra is the Co-Founder and CEO of Lumento Therapeutics. He completed a combined MD-PhD program at Harvard University and University of Groningen and has extensive experience in translational and clinical science. He aims to leverage his previous start-up experience and his MD-PhD background to develop the breakthrough therapies of Lumento.
Prof. Ben Feringa
Chief Scientific Officer
Professor Ben Feringa is the Co-Founder and Chief Scientific Officer of Lumento Therapeutics. He is a world-renowned scientist and was awarded the Nobel Prize in Chemistry in 2016. In addition to his highly successful research career, he previously co-founded Kiadis Pharma, which is now publicly traded. Professor Feringa is the founder of the scientific field of Photopharmacology and the research of his group has laid the foundation for the drug development platform of Lumento Therapeutics.
Mickel Hansen, PhD
Mickel Hansen is the Co-Founder and Technical Lead of Lumento Therapeutics. He obtained his PhD in Chemistry in the research group of Professor Feringa with a focus on Photopharmacology. As such, he is internationally recognized as an expert in the development and testing of several light-activatable compounds, including an anti-cancer agent for which he provided in vitro Proof of Concept.
Dusan Kolarski, PhD
Dusan Kolarski is the organic chemist of Lumento Therapeutics. He recently obtained his PhD in Photopharmacology in the research group of Professor Feringa, bringing a wealth of experience in synthesis and testing of light-activated compounds to the team. Before his PhD, he received his BSc degree in Chemistry at the University of Belgrade. He then pursued his MSc studies at ETH Zurich and did an internship at Novartis Institute for BioMedical Research in Basel.